A new, lifelike model of nerve fibers may serve as a platform to screen for experimental treatments that can promote myelin ...

Advances in diagnostics and disease-modifying therapies have significantly expanded treatment options for MS over the past 2 ...

Scientists hunting for treatments and cures for multiple sclerosis may have found an unlikely ally — the yak. The high-altitude, cold-hardy relative of the cow could be the key to a medical ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

The ACP received funding to help interpret research and support decisions about MS treatments for older adults with MS.

What causes gray matter loss in Multiple Sclerosis? New research identifies DNA damage in CUX2 neurons as a primary driver of MS progression.

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...

Significantly higher levels of HRQoL were reported in patients who lived in cities, had lower MS severity and fatigue, had higher cognitive processing speed, and had achieved higher educational ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...